Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

1.1K
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
1.1K
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

600
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
600
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

1.8K
Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
1.8K
Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

1.3K
Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
1.3K
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

726
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
726
Tissue Transplantation01:24

Tissue Transplantation

1.2K
Tissue transplantation is a significant medical procedure involving the transfer of cells, tissues, or organs from a donor to a recipient, with the primary aim of restoring lost functions. This procedure is crucial in treating a broad spectrum of diseases, including kidney diseases, liver failure, heart disease, and certain types of cancers.
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...
1.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Advertising in AI-Powered Clinical Decision Support Tools.

JAMA·2026
Same author

Randomized double-blind clinical trial evaluating the effectiveness and safety of secondary prophylaxis with oral vancomycin versus placebo in the prevention of recurrence of <i>clostridioides difficile</i> infection in patients receiving systemic antibiotic therapy (PREVAN trial).

JAC-antimicrobial resistance·2026
Same author

Clinical Presentation, Risk Factors and Outcome of Non-Tuberculous Mycobacteria Infection in Hematopoietic Stem-Cell Transplantation: A Multinational Case-Control Study.

Open forum infectious diseases·2026
Same author

Rezafungin for Salvage or Consolidation Therapy of Invasive Fungal Disease: Experience in Real-World Clinical Practice.

Mycoses·2026
Same author

Experience with isavuconazole in lung transplant recipients with <i>Aspergillus</i> isolation in respiratory tract specimens: A multicenter, observational study.

JHLT open·2025
Same author

False-positive results of the turbidimetric β-D-glucan assay in patients with bacteremia.

Diagnostic microbiology and infectious disease·2025

Related Experiment Video

Updated: Mar 12, 2026

Trans-vivo Delayed Type Hypersensitivity Assay for Antigen Specific Regulation
11:49

Trans-vivo Delayed Type Hypersensitivity Assay for Antigen Specific Regulation

Published on: May 2, 2013

16.7K

Tuberculosis and Transplantation.

José M Aguado1, José Tiago Silva1, Palash Samanta2

  • 1University Hospital 12 de Octubre, Unit of Infectious Diseases, 28041 Madrid, Spain.

Microbiology Spectrum
|November 5, 2016
PubMed
Summary

Tuberculosis (TB) is significantly more common in transplant recipients than the general population, posing unique challenges. Managing TB in these patients requires careful consideration of risk factors and drug interactions.

More Related Videos

A 3D Human Lung Tissue Model for Functional Studies on Mycobacterium tuberculosis Infection
10:10

A 3D Human Lung Tissue Model for Functional Studies on Mycobacterium tuberculosis Infection

Published on: October 5, 2015

19.5K
Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates
10:04

Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates

Published on: September 5, 2017

19.4K

Related Experiment Videos

Last Updated: Mar 12, 2026

Trans-vivo Delayed Type Hypersensitivity Assay for Antigen Specific Regulation
11:49

Trans-vivo Delayed Type Hypersensitivity Assay for Antigen Specific Regulation

Published on: May 2, 2013

16.7K
A 3D Human Lung Tissue Model for Functional Studies on Mycobacterium tuberculosis Infection
10:10

A 3D Human Lung Tissue Model for Functional Studies on Mycobacterium tuberculosis Infection

Published on: October 5, 2015

19.5K
Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates
10:04

Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates

Published on: September 5, 2017

19.4K

Area of Science:

  • Immunology
  • Infectious Diseases
  • Transplantation Medicine

Background:

  • Mycobacterium tuberculosis (TB) is an opportunistic pathogen with significantly higher incidence in transplant recipients.
  • Hematopoietic stem cell transplant (HSCT) and solid-organ transplant (SOT) recipients face 10-74 times greater TB risk compared to the general population.
  • TB in transplant recipients often presents as disseminated disease, with delayed diagnosis and increased treatment toxicity.

Purpose of the Study:

  • To review the epidemiology, clinical presentation, diagnostic considerations, and management strategies for TB in SOT and HSCT recipients.
  • To highlight specific risk factors for TB in both SOT and HSCT populations.
  • To address the complexities of managing active TB due to drug interactions with immunosuppressive therapy.

Main Methods:

  • Review of epidemiological data on TB incidence in transplant recipients.
  • Analysis of clinical presentations and diagnostic challenges.
  • Discussion of risk factors specific to SOT and HSCT.
  • Examination of management strategies, including latent TB treatment and active TB care.
  • Consideration of drug interactions between anti-TB agents and immunosuppressants.

Main Results:

  • TB incidence is substantially elevated in HSCT and SOT recipients.
  • Risk factors for TB vary between SOT and HSCT, including prior exposure and immunosuppression intensity.
  • Management of active TB is complicated by drug interactions with immunosuppressive therapy.
  • Latent TB infection requires appropriate treatment in at-risk transplant recipients.

Conclusions:

  • Transplant recipients are at high risk for TB, necessitating vigilant screening and management.
  • Identifying and mitigating specific risk factors is crucial for TB prevention in SOT and HSCT recipients.
  • Optimizing TB treatment requires careful management of drug interactions to balance infection control and immunosuppression.